HRP20070360B1 - Pharmaceutical compositions comprising drospirenone - Google Patents
Pharmaceutical compositions comprising drospirenoneInfo
- Publication number
- HRP20070360B1 HRP20070360B1 HRP20070360AA HRP20070360A HRP20070360B1 HR P20070360 B1 HRP20070360 B1 HR P20070360B1 HR P20070360A A HRP20070360A A HR P20070360AA HR P20070360 A HRP20070360 A HR P20070360A HR P20070360 B1 HRP20070360 B1 HR P20070360B1
- Authority
- HR
- Croatia
- Prior art keywords
- menopause
- estrogen
- drospirenone
- active ingredient
- pharmaceutical composition
- Prior art date
Links
- METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- METQSPRSQINEEU-HXCATZOESA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 title abstract 2
- 229960004845 drospirenone Drugs 0.000 title abstract 2
- 229940011871 estrogen Drugs 0.000 abstract 3
- 239000000262 estrogen Substances 0.000 abstract 3
- 101000605827 Homo sapiens Pinin Proteins 0.000 abstract 2
- 102100038374 Pinin Human genes 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 abstract 1
- 206010030247 Oestrogen deficiency Diseases 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- METQSPRSQINEEU-OLKMEILKSA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3C3C4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-OLKMEILKSA-N 0.000 abstract 1
- 210000004696 endometrium Anatomy 0.000 abstract 1
- 229960004766 estradiol valerate Drugs 0.000 abstract 1
- 230000009931 harmful effect Effects 0.000 abstract 1
- 238000002657 hormone replacement therapy Methods 0.000 abstract 1
- 230000009245 menopause Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Farmaceutska kompozicija sadržava kao prvi aktivni sastojak estrogen, kao što je estradiol valerat, u dostatnoj količini za tretiranje smetnji i simptoma povezanih s deficijencijom endogenog nivoa estrogena u žena, a kao sekundarni aktivni sastojak 6Ăź;7Ăź;15Ăź;16Ăź-dimetilen-3-okso-17α-preg-4-ene-21,17-karbolakton (drospirenon, DRSP) u dostatnoj količini za zaštitu endometrija od štetnog učinka estrogena koji je koristan za drugo, tretiranje žena u peri-menopauzi, menopauzi i post-menopauzi. Ta kompozicija može se koristiti kao hormonska nadomjesna terapija i može se aplicirati kao multi-fazni farmaceutski pripravak. Kombinirana terapija može obuhvaćati kontinuiranu, sekvencijalnu ili prekidanu aplikaciju, ili njihovu kombinaciju, DRSP i estrogena, svaku po izboru u mikroniziranom obliku.The pharmaceutical composition contains as a first active ingredient estrogen, such as estradiol valerate, in sufficient quantity to treat disorders and symptoms associated with endogenous estrogen deficiency in women, and as a secondary active ingredient 6Ăź; 7Ăź; 15Ăź; 16Ăź-dimethylene-3-oxo -17α-preg-4-ene-21,17-carbolactone (drospirenone, DRSP) in sufficient quantity to protect the endometrium from the harmful effect of estrogen that is beneficial for another, treating women in peri-menopause, menopause and post-menopause. This composition can be used as a hormone replacement therapy and can be administered as a multi-phase pharmaceutical composition. Combination therapy may include continuous, sequential or discontinued administration, or a combination of DRSPs and estrogens, each optionally in micronized form.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32576000P | 2000-01-18 | 2000-01-18 | |
EP00200183 | 2000-01-18 | ||
PCT/IB2001/000041 WO2001052857A1 (en) | 2000-01-18 | 2001-01-18 | Drospirenone for hormone replacement therapy |
Publications (2)
Publication Number | Publication Date |
---|---|
HRP20070360A2 HRP20070360A2 (en) | 2008-12-31 |
HRP20070360B1 true HRP20070360B1 (en) | 2014-11-21 |
Family
ID=38170612
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20070360AA HRP20070360B1 (en) | 2000-01-18 | 2007-08-17 | Pharmaceutical compositions comprising drospirenone |
Country Status (7)
Country | Link |
---|---|
AR (1) | AR035633A1 (en) |
CO (1) | CO5280075A1 (en) |
HR (1) | HRP20070360B1 (en) |
JO (1) | JO2334B1 (en) |
PE (1) | PE20011051A1 (en) |
SA (1) | SA01210754B1 (en) |
UA (2) | UA89180C2 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996003130A1 (en) * | 1994-07-27 | 1996-02-08 | Schering Aktiengesellschaft | Use of a progesterone antagonist and of a gestagen for the treatment of endometriosis or leiomyomata uteri |
WO1998027929A2 (en) * | 1996-12-20 | 1998-07-02 | Schering Aktiengesellschaft | Therapeutic gestagens for the treatment of premenstrual dysphoric disorder |
WO2001015701A1 (en) * | 1999-08-31 | 2001-03-08 | Schering Aktiengesellschaft | Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive |
-
2001
- 2001-01-11 JO JO200110A patent/JO2334B1/en active
- 2001-01-15 PE PE2001000035A patent/PE20011051A1/en active IP Right Grant
- 2001-01-17 CO CO01003045A patent/CO5280075A1/en not_active Application Discontinuation
- 2001-01-17 AR ARP010100199 patent/AR035633A1/en not_active Application Discontinuation
- 2001-01-18 UA UAA200612100A patent/UA89180C2/en unknown
- 2001-01-18 UA UA2002086809A patent/UA81388C2/en unknown
- 2001-03-21 SA SA01210754A patent/SA01210754B1/en unknown
-
2007
- 2007-08-17 HR HRP20070360AA patent/HRP20070360B1/en not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996003130A1 (en) * | 1994-07-27 | 1996-02-08 | Schering Aktiengesellschaft | Use of a progesterone antagonist and of a gestagen for the treatment of endometriosis or leiomyomata uteri |
WO1998027929A2 (en) * | 1996-12-20 | 1998-07-02 | Schering Aktiengesellschaft | Therapeutic gestagens for the treatment of premenstrual dysphoric disorder |
WO2001015701A1 (en) * | 1999-08-31 | 2001-03-08 | Schering Aktiengesellschaft | Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive |
Non-Patent Citations (1)
Title |
---|
MUHN P ET AL: "DROSPIRENONE: A NOVEL PROGESTOGEN WITH ANTIMINERALOCORTICOID AND ANTIANDROGENIC ACTIVITY PHARMACOLOGICAL CHARACTERIZATION IN ANIMAL MODELS" CONTRACEPTION, GERON-X, INC., LOS ALTOS, CA, US, vol. 51, no. 2, February 1995 (1995-02), pages 99-110, XP000908817 ISSN: 0010-7824 * |
Also Published As
Publication number | Publication date |
---|---|
HRP20070360A2 (en) | 2008-12-31 |
JO2334B1 (en) | 2006-06-28 |
AR035633A1 (en) | 2004-06-23 |
SA01210754B1 (en) | 2007-02-17 |
CO5280075A1 (en) | 2003-05-30 |
PE20011051A1 (en) | 2001-10-17 |
UA81388C2 (en) | 2008-01-10 |
UA89180C2 (en) | 2010-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ME00292B (en) | Drospirenone for hormone replacement therapy | |
KR20090080989A (en) | USE OF ESTRADIOL VALERATE OR 17beta-ESTRADIOL IN COMBINATION WITH DIENOGEST FOR ORAL THERAPY FOR MAINTAINING AND/OR INCREASING THE FEMALE LIBIDO | |
JP2010508275A5 (en) | ||
NZ516502A (en) | Administration of non-oral androgenic steroids to women having an elevated level of sex hormone binding globulin (SHBG) | |
KR20060126671A (en) | Extended use combination comprising estrogens and progestins | |
CA2467237C (en) | Method of preventing or treating benign gynaecological disorders | |
KR20120107492A (en) | Nestorone/estradiol transdermal gel | |
IL149448A0 (en) | New topical estrogen-progestogen compositions with a systemic effect | |
KR970704450A (en) | Use of a progesterone antagonist and gestagen to treat endometrial hyperplasia or uterine leiomyoma (Use of a Progesterone Antagonist and a Gestagen for Endometriosis or Leiomyomate Uteri) | |
JP2011001388A (en) | Composition including combination of aromatase inhibitor, progestin and estrogen, and its use for the treatment of endometriosis | |
EA200301022A1 (en) | HORMONAL REPLACEMENT THERAPY | |
TR199900764T2 (en) | A hormonal composition consisting of an estrogen compound and a progestational compound. | |
HRP20070360B1 (en) | Pharmaceutical compositions comprising drospirenone | |
HRP20020666A8 (en) | Drospirenone for hormone replacement therapy | |
CR6627A (en) | NEW CONTRACEPTIVE MEDICINAL PRODUCT AND ITS PREPARATION MODE | |
CA2248841C (en) | Sequential oestrogen/progesterone antagonist combination for hormone replacement therapy | |
Whitehead | Hormone replacement therapy with estradiol and drospirenone: an overview of the clinical data | |
Sivanandy et al. | Newer hormonal therapies: lower doses; oral, transdermal, and vaginal formulations. | |
SI20851B (en) | Mesoprogestins (progesterone receptor modulators) as a component of compositions for hormone replacement therapy (hrt) | |
TH134365B (en) | Drospirinone for hormone replacement therapy | |
AU2003206424B2 (en) | Sequential estrogen/progesterone antagonist combination for hormone replacement therapy | |
TH134365A (en) | Drospirinone for hormone replacement therapy | |
Moghadam et al. | Advances in menopausal hormonal therapy delivery systems: a comparative review | |
CA2215382A1 (en) | Once-a-month-injection as a depot contraceptive and for hormone replacement therapy for perimenopausal and premenopausal women | |
MXPA98007513A (en) | Sequencial combination of estrogen / antagonist of progesterone for therapy of replacement of hormo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
PNAN | Change of the applicant name, address/residence |
Owner name: BAYER PHARMA AG, DE |
|
B1PR | Patent granted | ||
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20190108 Year of fee payment: 19 |
|
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20191227 Year of fee payment: 20 |
|
PB20 | Patent expired after termination of 20 years |
Effective date: 20210118 |